Company News 

Early-stage products prove problematic for BTG

Early-stage products prove problematic for BTG

The ongoing problems in BTG’s (BTG) early-stage interventional medicine business have landed investors with a conundrum: do the struggles of PneumRx (an experimental lung disease treatment) and Varithena (a novel therapy for varicose veins) have any bearing on the long-term investment case or are recent share price weaknesses an opening for new investors?

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now